Tiempo de reevaluar los bisfosfonatos y de revisar la regulación de medicamentos y nuestras actitudes

1. Outeriño-Fernández, A. La osteonecrosis asociada al tratamiento con bisfosfonatos en osteoporosis primaria. Revisión de la literatura. An Sist Sanit Navar 2013: 36: 87-97

https://doi.org/10.4321/S1137-66272013000100009

2. Vlad SC, Zhu Y, Niu J, et al. Bisphosphonate use may be a risk factor for osteonecrosis at any site: a self-controlled case series analysis [abstract]. 27th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Chicago, 2011;[274]

3.Genant HK, Jergas M, Palermo L, Nevitt M, San Valentin R, Black D et al. Comparison of Semiquantitative Visual and Quantitative Morphometric Assessment of Prevalent and Incident Vertebral Fractures in Osteoporosis. J Bone and Mineral Research 1996; 11: 984-996.

https://doi.org/10.1002/jbmr.5650110716

4. Therapeutics initiative. A systematic review of the efficacy of bisphosphonates. Therapeutics Letter 2011; 83: 1-2.

5. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al. Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-2938.

https://doi.org/10.1001/jama.296.24.2927

6. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis. Where do we go from here? N Engl J Med 2012

https://doi.org/10.1056/NEJMp1202619

May 9, 2012 (10.1056/NEJMp1202619)

7. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. JBMR, doi: 10.1359/JBMR.081247.

https://doi.org/10.1359/jbmr.081247

8. Abrahamsen B, Eiken P, and Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: A register-based national cohort analysis. J Clin Endocrin Metab doi:10.1210/jc.2010-1571.

https://doi.org/10.1210/jc.2010-1571

9. Erviti J, Alonso Á, Gorricho J et al. Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study. BMJ Open 2013; 3:e002084. doi:10.1136/bmjopen-2012-002084

https://doi.org/10.1136/bmjopen-2012-002084

10. Erviti J, Alonso Á, Oliva B, et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. BMJ Open 2013;3:e002091. doi:10.1136/bmjopen-2012-002091

https://doi.org/10.1136/bmjopen-2012-002091

11. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY.

Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301.

https://doi.org/10.1210/jc.2004-0952

12. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002; 288:321-333. doi:10.1001/jama.288.3.321.

https://doi.org/10.1001/jama.288.3.321

13. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254.

https://doi.org/10.1136/bmj.312.7041.1254

14. Agencia Española de Medicamentos y Productos Sanitarios AEMPS. Calcitonina: suspensión de la comercialización de los preparados intranasales y restricción del uso de los preparados inyectables a tratamientos de corta duración. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2013/NI-MUH_FV_09-2013-calcitonina.htm